Marktanalyse - France Pharmaceutical Market Overview – Austerity measures will impact pharmaceutical market growth

Introduction

The prescription pharma market in France was valued at $38.8bn in sales in 2009, having by 3.1% (CAGR; 2005—09). Key growth drivers include growing use of chronic high-value innovative treatments driven by an aging population, high public healthcare expenditure as proportion of total healthcare expenditure, physician preference for prescribing branded drugs as well as high patient brand loyalty.
Features and benefits

* Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement and intellectual property in France
* Assesses the size of the French pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies
* Examines the French generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion
* Quantifies the R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis
Highlights

Despite having a higher birth rate than most European countries, with its ageing population France is encountering difficulties in handling its health account deficit, a situation made worse by the economic downturn. Hence France has turned towards social system reforms and austerity measures.Despite having a favourable market for innovative and expensive drugs a range of cost-cutting measures such as pricing and reimbursement cuts will have a negative impact on the French pharmaceutical market.Once considered the immature generics market, France has considerably increased its generics uptake although there is still a significant scope for improvement. Physicians’ resistance to generics use remains the greatest obstacle with adequate physicians’ financial incentives necessary in the future.
Your key questions answered

* Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access in France
* Quantify the size and growth of the prescription pharmaceutical market in France, analyzing key therapy areas, brands and companies
* Assess drivers and resistors of generic and biosimilars uptake in France

Executive Summary

Introduction

Strategic scoping and focus

Key findings — healthcare drivers and resistors in France

France — Socio-demographic and economic analysis

France — Healthcare system and drug regulatory analysis

France — Prescription pharmaceutical sales analysis

France — Drug expiry analysis

France — Pharmaceutical Industry Infrastructure analysis

Related reports

Upcoming related reports

2. FRANCE — SOCIO-DEMOGRAPHIC AND ECONOMIC ANALYSIS

France — Key findings

Socio-demographic trends

Socioeconomic trends

France — Demographic trends

France’s population is increasing as the number of elderly people grows

The birth rate in France is higher than the rest of the EU

The number of elderly individuals and life expectancy are both increasing in France

France — Disease burden

A shift in diet is responsible for growing rates of heart disease, diabetes, and obesity

Cancer is responsible for high death rates in France

Alzheimer’s disease is associated with growing morbidity and mortality in France

France — Political climate

Corruption claims have shaken the public’s faith in France’s presidency

France — Economic climate

France’s relatively high productivity rates are being threatened by strike action against pension reforms

France’s budget deficit is projected to reach 8% of GDP in 2010

France — Business environment

The business environment in France is considered strong, but rigid labor laws keep unemployment high

Corporate income tax is relatively high in France

France welcomes foreign direct investment

French pharma industry is well developed but still has its downsides

The unemployment rate in France has continued to rise since the recession

3. FRANCE — HEALTHCARE SYSTEM AND DRUG REGULATORY ANALYSIS

France — Key findings

Healthcare expenditure

Healthcare insurance

Regulatory issues

Pricing and reimbursement issues

France — Healthcare expenditure

France has a higher than OECD average healthcare spend per capita, and a higher pharmaceutical spend

France — Insurance and healthcare system

France has a social security system provided by three main health insurance schemes

Primary care versus hospital care in France

France — Regulatory issues

Drug approval and regulatory processes in France

The AFSSAPS is the national drugs regulatory body in France

AFFSAPS has received some criticism for being too lax on conflicts of interest

Intellectual property — patents are valid for 20 years from date of application in France

Data exclusivity issues in France — the 8+2+1 rule

Drug counterfeiting in France — the country is taking measures to improve transparency of the supply chain

France — Pricing and reimbursement

France has employed a range of cost-cutting tools

Key pricing and reimbursement bodies in France

High pharmaceutical expenditure in France has led to an evolving pricing and reimbursement process

The prices of most medicines are controlled in France

Pricing issues — pricing and reimbursement processes in France are interconnected

Reimbursement issues in France — reimbursement is decided on by UNCAM

4. FRANCE — PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS

France — Key findings

Pharmaceutical market size

Leading therapy areas

Leading pharmaceutical brands

Leading pharmaceutical companies

France — Pharmaceutical market size

France — Leading therapy areas

Central nervous system was the largest therapy area in terms of sales

Oncology drugs have shown the fastest growth rates

Gastroenterology drugs have shown the sharpest decline in growth rates

France — Leading pharmaceutical brands

Plavix is the top-selling pharmaceutical brand, although its position will be jeopardized due to intensifying generic competition

Lipitor will see a sharp decline in sales following the imminent patent expiry in 2011

Avastin’s impressive growth rates are set to continue in the future

France — Leading pharmaceutical companies

Sanofi-Aventis is the largest pharmaceutical company in France

Mylan is the largest generics company in France

The top 10 France-based pharmaceutical companies

5. FRANCE — DRUG EXPIRY ANALYSIS

France — Key findings

Generics market

Brand erosion post patent expiry

Biosimilars market

France — Generics market dynamics

France generics volume uptake

France generics value uptake

France generics market size

France — Generics drivers and resistors

Physicians are the key to increasing generic uptake in France

Proposed price cuts will damage generic players

Reference pricing increases competition from original brands…

…but changes to the reference pricing system could increase generic penetration significantly

The repertoire has driven generics uptake; however, physicians are impeding its wider usage

Dominance of branded generics limits uptake for smaller players

Pharmacists are increasingly using purchasing groups, since pharmacy chains are not permitted

Publicity campaigns are used to drive generic uptake patients, but brand loyalty is a significant barrier

Raids on generic companies and allegations of illegal activities hamper uptake

France — Key generics players

Mylan is a market leader in France

Teva to become a strong force in French generic sales

Opportunities for the generics industry

France — Small molecule brand erosion

Overview of drugs analyzed

Mean level of brand erosion in France

Brand erosion in the French retail and hospital setting

Brand erosion by therapy area in France

Brand erosion by drug formulation in France

France — Biosimilars market dynamics

Drivers and resistors to biosimilar uptake in France

Originators maintain prices in the face of biosimilar competition

Approved biosimilars

Biosimilar epoetin

Biosimilar filgrastim

Biosimilar somatropin

Key players in the French biosimilars market

Opportunities for the biosimilar industry

6. FRANCE — PHARMACEUTICAL INDUSTRY INFRASTRUCTURE ANALYSIS

France — Key findings

Pharmaceutical industry infrastructure overview

France — Pharmaceutical industry infrastructure overview

The manufacturing sector in France is increasingly focused on innovative biologics production

France is set to become an R&D hotspot

R&D and manufacturing strategies in France

France — Key company infrastructure

Sanofi-Aventis

Pfizer

Merck & Co.

Roche

Novartis

AstraZeneca

GlaxoSmithKline

Servier

Mylan

Johnson & Johnson

7. BIBLIOGRAPHY

France — Executive summary

Publications and online articles

Datamonitor reports and products

France — Socio-demographic and economic analysis

Publications and online articles

France — Healthcare systems and regulations

Publications and online articles

Datamonitor reports and products

France — Prescription pharmaceutical sales

Publications and online articles

Datamonitor reports and products

France — Drug expiry analysis

Publications and online articles

Datamonitor reports and products

France — Pharmaceutical industry infrastructure analysis

Publications and online articles

Datamonitor reports and products

APPENDIX

Exchange rates used in this report

Brand erosion — additional data and analysis

Brand erosion — methodology

Datamonitor prescription pharmaceutical definition and therapy area classification

• Global Medical Dressing Market
• Global Medication Management System Market 2012-2016
• ICT Spend Predictions in Large Brazilian Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large Canadian Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large French Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large German Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large Mexican Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large UK Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Large US Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized Brazilian Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized Canadian Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized French Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized German Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized Mexican Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized UK Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Medium-sized US Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small Brazilian Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small Canadian Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small French Healthcare Providers - Estimated ICT budget breakdowns in 2013
• ICT Spend Predictions in Small German Healthcare Providers - Estimated ICT budget breakdowns in 2013